Collectively, these markets account for 38% of adults living with obesity globally
The SELECT trial result - 20% reduction in major cardiovascular events with weekly semaglutide 2.4mg in adults with established cardiovascular disease plus overweight/obesity - was the first time a weight-loss medication demonstrated cardiovascular outcome benefits in a major randomized controlled trial
[DOI] [PubMed] [Google Scholar] 22.Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, Hu FB, Hubbard VS, Jakicic JM, Kushner RF, Loria CM, Millen BE, Nonas CA, Pi-Sunyer FX, Stevens J, Stevens VJ, Wadden TA, Wolfe BM, Yanovski SZ, Jordan HS, Kendall KA, Lux LJ, Mentor-Marcel R, Morgan LC, Trisolini MG, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen W, Smith SC, Tomaselli GF, American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Franco et al., 2022)
Four triagonists have been developed (MAR423, retatrutide, SAR441225, and HM15211) and are currently undergoing preclinical trials to verify their potency and biological safety
